组蛋白去乙酰化酶：视网膜变性中的治疗靶点
Histone Deacetylase: Therapeutic Targets in Retinal Degeneration.
作者信息
Daly Conor, Yin Jun, Kennedy Breandán N
机构信息
School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, 4, Dublin, Ireland.
Department of Genetics, Yale University School of Medicine, 06520, New Haven, CT, USA.
出版信息
Adv Exp Med Biol. 2016;854:455-61. doi: 10.1007/978-3-319-17121-0_61.
Previous studies report that retinitis pigmentosa (RP) patients treated with the histone deacetylase inhibitor (HDACi) valproic acid (VPA) present with improved visual fields and delayed vision loss. However, other studies report poor efficacy and safety of HDACi in other cohorts of retinal degeneration patients. Furthermore, the molecular mechanisms by which HDACi can improve visual function is unknown, albeit HDACi can attenuate pro-apoptotic stimuli and induce expression of neuroprotective factors. Thus, further analysis of HDACi is warranted in pre-clinical models of retinal degeneration including zebrafish. Analysis of HDAC expression in developing zebrafish reveals diverse temporal expression patterns during development and maturation of visual function.
先前的研究报告称，接受组蛋白去乙酰化酶抑制剂（HDACi）丙戊酸（VPA）治疗的视网膜色素变性（RP）患者视野得到改善，视力丧失延迟。然而，其他研究报告称HDACi在其他视网膜变性患者队列中的疗效和安全性较差。此外，尽管HDACi可以减弱促凋亡刺激并诱导神经保护因子的表达，但其改善视觉功能的分子机制尚不清楚。因此，有必要在包括斑马鱼在内的视网膜变性临床前模型中对HDACi进行进一步分析。对发育中的斑马鱼HDAC表达的分析揭示了视觉功能发育和成熟过程中不同的时间表达模式。
Zotero 插件